The invention discloses an
arginine-based method for preventing aggregation of omalizumab. The
arginine-based method for preventing aggregation of the omalizumab comprises the following steps: (1) preparing instruments: before experiments, preparing an electronic scale, a
pH meter, a chromatographic
system, a
pipette, a rProtein A filler and an XK50 / 20
chromatographic column (As is 1.114, HETP is0.0213, CV is 175, and H is 8.9); (2) preparing consumable materials: preparing the materials, and producing solutions for the experiments; (3) conducting the
chromatography experiment: conducting thechromatography experiment through the steps of rinsing, balancing, sample loading, leaching, eluting, regenerating, balancing before disinfecting, disinfecting, balancing after disinfecting, secondary rinsing and storing; (4) conducting the aggregation-preventing experiment: adjusting a pH value through diluted
hydrochloric acid, and after centrifugal treatment is conducted, adding
Tris dropwisefor observation; (5) analyzing results: analyzing the results obtained at different contents; and (6) drawing a conclusion from analysis of the results. The
arginine-based method for preventing aggregation of the omalizumab covers preparation of the instruments and the consumable materials, the
chromatography experiment, the aggregation-preventing experiment and drawing of the conclusion from accurate analysis of the results, the arginine-based method for preventing aggregation of the omalizumab can be reasonably and accurately expressed, and thinking is precise.